Immunonutritional diet modulates natural killer cell activation and Th17 cell distribution in patients with gastric and esophageal cancer

Nutrition

Volumn 27, Issue 2, 2011, Pages 146-152

  Maruyama, Takanori ^a   Mimura, Kousaku ^a   Izawa, Shinichiro ^a   Shiba, Shugo ^a   Watanabe, Mitsuaki ^a   Kawaguchi, Yoshihiko ^a   Fujii, Hideki ^a   Kono, Koji ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

CD16; CD56dim; Immunonutrition; Natural killer cell; NKG2D; Type 17 helper T cell

Indexed keywords

ARGININE; CD16 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 21; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; OMEGA 3 FATTY ACID; RNA;

AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ACTIVATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNONUTRITION; MALE; NATURAL KILLER CELL; NUTRITION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STOMACH CANCER; TH17 CELL; UPREGULATION;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DIET; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NUTRITIONAL STATUS; STOMACH NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 78650813596     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2010.07.007     Document Type: Article

References (46)

1. Whooley B.P., Law S., Murthy S.C., Alexandrou A., Wong J. Analysis of reduced death and complication rates after esophageal resection. Ann Surg 2001, 233:338-344.
2. Law S., Wong K.H., Kwok K.F., Chu K.M., Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 2004, 240:791-800.
3. Nakamura K., Kariyazono H., Komokata T., Hamada N., Sakata R., Yamada K. Influence of preoperative administration of omega-3 fatty acid-enriched supplement on inflammatory and immune responses in patients undergoing major surgery for cancer. Nutrition 2005, 21:639-649.
4. Nakamura K., Moriyama Y., Kariyazono H., Hamada N., Toyohira H., Taira A., et al. Influence of preoperative nutritional state on inflammatory response after surgery. Nutrition 1999, 15:834-841.
5. Gianotti L., Braga M., Gentilini O., Balzano G., Zerbi A., Di Carlo V. Artificial nutrition after pancreaticoduodenectomy. Pancreas 2000, 21:344-351.
6. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN 2002, 26. 1SA-138.
7. Weimann A., Braga M., Harsanyi L., Laviano A., Ljungqvist O., Soeters P., et al. ESPEN guidelines on enteral nutrition: surgery including organ transplantation. Clin Nutr 2006, 25:224-244.
8. Senkal M., Zumtobel V., Bauer K.H., Marpe B., Wolfram G., Frei A., et al. Outcome and cost-effectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery: a prospective randomized study. Arch Surg 1999, 134:1309-1316.
9. Gianotti L., Braga M., Frei A., Greiner R., Di Carlo V. Health care resources consumed to treat postoperative infections: cost saving by perioperative immunonutrition. Shock 2000, 14:325-330.
10. Klek S., Kulig J., Sierzega M., Szybinski P., Szczepanek K., Kubisz A., et al. The impact of immunostimulating nutrition on infectious complications after upper gastrointestinal surgery: a prospective, randomized, clinical trial. Ann Surg 2008, 248:212-220.
11. Senkal M., Kemen M., Homann H.H., Eickhoff U., Baier J., Zumtobel V. Modulation of postoperative immune response by enteral nutrition with a diet enriched with arginine, RNA, and omega-3 fatty acids in patients with upper gastrointestinal cancer. Eur J Surg 1995, 161:115-122.
12. Braga M., Gianotti L., Radaelli G., Vignali A., Mari G., Gentilini O., et al. Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized double-blind phase 3 trial. Arch Surg 1999, 134:428-433.
13. Barber M.D. Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation. Nutrition 2001, 17:751-755.
14. Braga M., Gianotti L., Vignali A., Di Carlo V. Immunonutrition in gastric cancer surgical patients. Nutrition 1998, 14:831-835.
15. Gianotti L., Braga M., Fortis C., Soldini L., Vignali A., Colombo S., et al. A prospective, randomized clinical trial on perioperative feeding with an arginine-, omega-3 fatty acid-, and RNA-enriched enteral diet: effect on host response and nutritional status. JPEN 1999, 23:314-320.
16. Tepaske R., Velthuis H., Oudemans-van Straaten H.M., Heisterkamp S.H., van Deventer S.J., Ince C., et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet 2001, 358:696-701.
17. Wu G.H., Zhang Y.W., Wu Z.H. Modulation of postoperative immune and inflammatory response by immune-enhancing enteral diet in gastrointestinal cancer patients. World J Gastroenterol 2001, 7:357-362.
18. Sobin LH, Wittekind CH, eds. TNM Classification of Malignant Tumors. 5th ed. International Union Against Cancer (UICC). New York: Wiley; 1997:59-62.
19. Harlin H., Hanson M., Johansson C.C., Sakurai D., Poschke I., Norell H., et al. The CD16-CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset. J Immunol 2007, 179:4513-4519.
20. Nagler A., Lanier L.L., Cwirla S., Phillips J.H. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989, 143:3183-3191.
21. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
22. Ichihara F., Kono K., Takahashi A., Kawaida H., Sugai H., Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003, 9:4404-4408.
23. Mizukami Y., Kono K., Kawaguchi Y., Akaike H., Kamimura K., Sugai H., et al. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008, 98:148-153.
24. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005, 11:8326-8331.
25. Watanabe M., Kono K., Kawaguchi Y., Mizukami Y., Mimura K., Maruyama T., et al. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer 2009, 102:520-529.
26. Kemen M., Senkal M., Homann H.H., Mumme A., Dauphin A.K., Baier J., et al. Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic acid-supplemented diet versus placebo in cancer patients: an immunologic evaluation of Impact. Crit Care Med 1995, 23:652-659.
27. van der Hulst R.R., van Kreel B.K., von Meyenfeldt M.F., Brummer R.J., Arends J.W., Deutz N.E., et al. Glutamine and the preservation of gut integrity. Lancet 1993, 341:1363-1365.
28. Daly J.M., Lieberman M.D., Goldfine J., Shou J., Weintraub F., Rosato E.F., et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery 1992, 112:56-67.
29. Braga M., Vignali A., Gianotti L., Cestari A., Profili M., Carlo V.D. Immune and nutritional effects of early enteral nutrition after major abdominal operations. Eur J Surg 1996, 162:105-112.
30. Hall J.C., Heel K., McCauley R. Glutamine. Br J Surg 1996, 83:305-312.
31. Nakamura M., Iwahashi M., Takifuji K., Nakamori M., Naka T., Ishida K., et al. Optimal dose of preoperative enteral immunonutrition for patients with esophageal cancer. Surg Today 2009, 39:855-860.
32. Takeuchi H., Ikeuchi S., Kawaguchi Y., Kitagawa Y., Isobe Y., Kubochi K., et al. Clinical significance of perioperative immunonutrition for patients with esophageal cancer. World J Surg 2007, 31:2160-2167.
33. Carbone E., Neri P., Mesuraca M., Fulciniti M.T., Otsuki T., Pende D., et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiplemyeloma cell recognition by natural killer cells. Blood 2005, 105:251-258.
34. Pende D., Spaggiari G.M., Marcenaro S., Martini S., Rivera P., Capobianco A., et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005, 105:2066-2073.
35. Pende D., Cantoni C., Rivera P., Vitale M., Castriconi R., Marcenaro S., et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001, 31:1076-1086.
36. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
37. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
38. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 2006, 6:329-333.
39. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
40. van de Veerdonk F.L., Gresnigt M.S., Kullberg B.J., van der Meer J.W., Joosten L.A., Netea M.G. Th17 responses and host defense against microorganisms: an overview. BMB Rep 2009, 42:776-787.
41. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
42. Dubin P.J., Kolls J.K. Th17 cytokines and mucosal immunity. Immunol Rev 2008, 226:160-171.
43. O'Quinn D.B., Palmer M.T., Lee Y.K., Weaver C.T. Emergence of the Th17 pathway and its role in host defense. Adv Immunol 2008, 99:115-163.
44. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007, 178:6730-6733.
45. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
46. Derhovanessian E., Adams V., Hahnel K., Groeger A., Pandha H., Ward S., et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009, 125:1372-1379.